These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rifampin. Sanders WE Ann Intern Med; 1976 Jul; 85(1):82-6. PubMed ID: 937928 [TBL] [Abstract][Full Text] [Related]
3. [The pharmacokinetics of rifampicin in the intermittent treatment of patients with pulmonary tuberculosis. 2. The effect of rifampicin on the course of therapy for mycobacteriosis and non-tubercular infectious diseases]. Eule H; Werner E; Winsel K; Iwainsky H Pharmazie; 1985 Apr; 40(4):276-7. PubMed ID: 4011667 [No Abstract] [Full Text] [Related]
5. Rifampin: a semisynthetic derivative of rifamycin--a prototype for the future. Lester W Annu Rev Microbiol; 1972; 26():85-102. PubMed ID: 4562819 [No Abstract] [Full Text] [Related]
6. Chemical and biological properties of rifampicin. Furesz S Antibiot Chemother; 1970; 16():316-51. PubMed ID: 5002304 [No Abstract] [Full Text] [Related]
7. Clinical experience of the treatment of drug-resistant pulmonary tuberculosis with rifampicin combined with ethambutol and capreomycin. Wäre M; Heinivaara O; Elo R; Tala E Scand J Respir Dis Suppl; 1969; 69():59-63. PubMed ID: 4906375 [No Abstract] [Full Text] [Related]
8. Current concepts in therapy: rifampin. Riley HD South Med J; 1973 Feb; 66(2):273-5. PubMed ID: 4687602 [No Abstract] [Full Text] [Related]
9. The John Barnwell Lecture. The chemotherapy of bacterial respiratory infections. Crofton J Am Rev Respir Dis; 1970 Jun; 101(6):841-59. PubMed ID: 4914352 [No Abstract] [Full Text] [Related]
10. The Australian rifampicin trial. Proust AJ Med J Aust; 1971 Jul; 2(2):85-94. PubMed ID: 4999365 [No Abstract] [Full Text] [Related]
11. [Rifampicin in the retreatment of severe cavitary pulmonary tuberculosis. 2. Drug resistance, drug concentration in blood and side effects]. Baba H; Takahashi R; Azuma Y Kekkaku; 1971 Dec; 46(12):481-9. PubMed ID: 5004601 [No Abstract] [Full Text] [Related]
12. Rifampicin. Polascik M; Golden B Ann Ophthalmol; 1971 Aug; 3(8):877-82. PubMed ID: 5005929 [No Abstract] [Full Text] [Related]
13. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections. Vall-Spinosa A; Lester W; Moulding T; Davidson PT; McClatchy JK N Engl J Med; 1970 Sep; 283(12):616-21. PubMed ID: 4988918 [No Abstract] [Full Text] [Related]
14. [A new antitubercular agent: rifampicin]. Favez G Schweiz Rundsch Med Prax; 1970 Feb; 59(8):296-7. PubMed ID: 4996719 [No Abstract] [Full Text] [Related]
15. [The use of rifampicin in urology]. Germinale T; Moramarco E Arch Maragliano Patol Clin; 1969; 25(5):423-6. PubMed ID: 5395559 [No Abstract] [Full Text] [Related]
16. Toxicologic and pharmacologic aspects of rifampin. Radner DB Chest; 1973 Aug; 64(2):213-6. PubMed ID: 4199024 [No Abstract] [Full Text] [Related]
17. [Tolerance of rifampicin in long-term treatment of patients with pulmonary tuberculosis]. Fokina LV; Vusygina RN; Antosik OD Probl Tuberk; 1976 Feb; (21):34-9. PubMed ID: 1264980 [No Abstract] [Full Text] [Related]
19. [The optimal use of rifampicin in the polychemotherapy of pulmonary tuberculosis, with special reference to its liver-damaging potential: considerations and case studies]. Salvati F; Mugnaini L; Altieri AM; De Marinis F Clin Ter; 1979 Jan; 88(1):45-50. PubMed ID: 436377 [No Abstract] [Full Text] [Related]
20. The Australian rifampicin trial. Proust A; Evans C Med J Aust; 1972 Oct; 2(16):861-7. PubMed ID: 4647286 [No Abstract] [Full Text] [Related] [Next] [New Search]